Last reviewed · How we verify

NCT05116280

MACE and PE in Elective Primary TKA & THA

Completed Last updated 11 November 2021
What this trial tests

trial in Cardiovascular Complication in 200 participants. Completed in 30 January 2019.

Timeline
1 January 2018
Primary endpoint
31 December 2018
30 January 2019

Quick facts

Lead sponsorUniversity of Thessaly
StatusCompleted
Study typeOBSERVATIONAL
Enrollment200
Start date1 January 2018
Primary completion31 December 2018
Estimated completion30 January 2019
Sites1 location across Greece

Conditions studied

Sponsor

University of Thessaly

Who can join

Eligibility, any sex, with Cardiovascular Complication or Pulmonary Embolism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study ought to identify the occurence of the major adverse cardiovascular events (MACE) and the pumonary emoblism (PE) in patients undergoing elective primary THA \& TKA

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cardiovascular Complication

Currently open trials in the same condition.

Other University of Thessaly trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05116280.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing